Company news
Mustang Bio, Inc. news in 2021
Mustang Bio, Inc.'s news releases, calls and decks from 2021, newest first.
Mustang Bio Added to the NASDAQ Biotechnology Index
December 15, 2021
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
December 12, 2021
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
December 8, 2021
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
November 11, 2021
Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency
November 9, 2021
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
November 3, 2021
Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas
October 31, 2021
Mustang Bio to Participate in Chardan’s Virtual 5th Annual Genetic Medicines Conference
September 29, 2021
Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences
September 27, 2021
Mustang Bio to Participate in Three September 2021 Investor Conferences
September 8, 2021
Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights
August 15, 2021
Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology
August 11, 2021
Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
August 1, 2021
Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive
June 16, 2021
Mustang Bio to Present at the Raymond James Human Health Innovation Conference
June 15, 2021
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
June 10, 2021
Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
June 6, 2021
Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
May 17, 2021
Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 13, 2021
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress
May 11, 2021
Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy
May 9, 2021
Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit
April 20, 2021
Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
March 23, 2021
Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences
March 3, 2021
Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
February 25, 2021
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
February 1, 2021
Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences
January 4, 2021